证券日报网讯 8月25日晚间，西藏药业发布公告称，2025年半年度利润分配方案为A股每股现金红利 0.881元（含税），股权登记日为2025年8月29日，除权（息）日为2025年9月1日。 （编辑 姚尧） ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-028 重要内容提示： 西藏诺迪康药业股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 股东大会召开日期：2025年9月2日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票系统 (二)股东大会召集人：董事会 本公司于 2025 年 8 月 14 日召开第八届董事会第十次会议，审议通过了《董事会提议 召开 2025 年第一次临时股东大会的议案》，公司将于 2025 年 9 月 2 日召开 2025 年第一 次临时股东大会，并发布了关于召开 2025 年第一次临时股东大会的相关通知（详见公司 于 2025 年 8 月 16 日发布在《中国证券报》《上海证券报》《证券时报》及上海证券交易 所网站 www.sse.com.cn 的相关公告）。为确保公司股东充分了解本次股东大会的相关信 息，现将有关事项提示公告如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第一次临时股东大会 ...

证券代码：600211 证券简称：西藏药业 公告编号：2025-029 西藏诺迪康药业股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.881元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/8/29 | － | 2025/9/1 | 2025/9/1 | 差异化分红送转：否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 4 月 8 日的2024年年度股东大会授权并经公司第八 届董事会第十次会议审议通过。 公司 2024 年年度股东大会已授权董事会在 2025 年中期和第三季度报告后，在不影响 公司正常经营和后续发展的情况下，根据实际情况适当增加现金分红频次，制定并实施具 体的现金分红方案，分红上限不超过相应期间归属于上市公司股东的净利润。该议案无需 提交股东大会 ...

西藏诺迪康药业股份有限公司 2025 年第一次临时股东大会文件 以上议案，请各位股东审议。 1 | | | 议案一： 关于取消监事会的议案 各位股东： 根据中国证监会《关于新公司法配套制度规则实施相关过渡期安排》，上市公司应当在 2026 年 1 月 1 日前，按照《公司法》及证监会配套制度规则等规定，在公司章程中规定在 董事会中设审计委员会，行使《公司法》规定的监事会的职权，不设监事会或者监事。公 司按照上述规定，结合《上市公司章程指引》（2025 年 3 月修订）《上海证券交易所股票上 市规则》（2025 年 4 月修订）等有关法律、法规、规范性文件，公司拟取消监事会，由审 计委员会行使《公司法》规定的监事会的职权，相应废止公司《监事会议事规则》。 公司监事会取消后，姚沛先生不再担任公司职工监事、监事会主席；唐甜甜女士、章 婷女士不再担任公司监事。截至本公告披露之日，姚沛先生、唐甜甜女士、章婷女士未持 有公司股份，不存在应当履行而未履行的承诺事项。 西藏诺迪康药业股份有限公司 2025 年 9 月 2 日 3 议案二： 关于修订《公司章程》的议案 各位股东： 根据《公司法》（2023年12月修订）《上市公 ...

Core Insights - Tibet Pharmaceutical has evolved from its establishment in 1999 to a modern pharmaceutical company integrating R&D, production, and sales, contributing significantly to the modernization of ethnic medicine and rural revitalization [1][2] - The company reported a revenue of 16.51 billion yuan and a net profit of 5.43 billion yuan for the first half of 2025, with a total revenue of 28.07 billion yuan and a net profit of 10.51 billion yuan in 2024, marking a year-on-year growth of 31.26% [1][2] - Tibet Pharmaceutical is recognized as a pioneer in the modernization of Tibetan medicine, with a focus on cardiovascular treatments and a global marketing network spanning over 40 countries [2] Company Development - Since its inception, Tibet Pharmaceutical has established a comprehensive management platform covering R&D, production, and marketing, with nine subsidiaries and a focus on modern Tibetan medicine, biopharmaceuticals, and innovative chemical drugs [2] - The company has achieved several industry firsts, including the development of "New Active Substance," the first gene-engineered drug for acute heart failure in China, and the inclusion of its unique Tibetan medicine "Nodikon Capsule" in national essential drug and medical insurance directories [2] Social Responsibility - Tibet Pharmaceutical has contributed significantly to local development, with a total tax contribution of 28.99 billion yuan since its listing, of which 26.08 billion yuan was paid in Tibet, accounting for 89.96% of the total [2] - The company actively supports rural revitalization through initiatives that combine industry, livelihood, and culture, including the artificial cultivation of Tibetan medicinal materials to enhance local farmers' income while protecting the fragile ecosystem [3] - Employment support initiatives include partnerships with educational institutions and training programs for Tibetan students, fostering local talent and promoting community development [3]

Group 1 - The stock price of Xizang Pharmaceutical is reported at 46.04 yuan, down 1.62% from the previous trading day, with a trading volume of 98,714 hands and a transaction amount of 454 million yuan [1] - Xizang Pharmaceutical operates in the biopharmaceutical industry, focusing on the research, production, and sales of traditional Chinese medicine, Tibetan medicine, and chemical drugs [1] - In the first half of 2025, the company invested 300 million yuan to acquire a 13.04% stake in Jiangsu Chentai Pharmaceutical, which is developing Zolertinib, the world's first drug targeting advanced non-small cell lung cancer with central nervous system metastasis [1] Group 2 - On August 22, the net outflow of main funds was 38.92 million yuan, with a cumulative net outflow of 97.81 million yuan over the past five trading days [1]

8月22日，西藏药业盘中下跌2.01%，截至10:12，报45.86元/股，成交1.58亿元，换手率1.06%，总市值 147.82亿元。 资金流向方面，主力资金净流出1537.77万元，特大单买入540.60万元，占比3.43%，卖出701.54万元， 占比4.45%；大单买入2704.63万元，占比17.15%，卖出4081.46万元，占比25.88%。 西藏药业今年以来股价涨27.57%，近5个交易日跌2.32%，近20日涨14.94%，近60日涨26.62%。 资料显示，西藏诺迪康药业股份有限公司位于西藏自治区拉萨经济技术开发区A区广州路3号,四川省成 都市锦江区三色路427号，成立日期1999年7月14日，上市日期1999年7月21日，公司主营业务涉及医药 制造。主营业务收入构成为：药品销售99.80%，其他(补充)0.20%。 西藏药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：医疗器械、中盘、 融资融券、高派息、中药等。 截至6月30日，西藏药业股东户数4.52万，较上期减少8.08%；人均流通股7132股，较上期增加8.79%。 2025年1月-6月，西藏药业实现营业收 ...

Group 1 - The stock price of Tibet Pharmaceutical as of August 21, 2025, is 46.80 yuan, down by 0.28 yuan from the previous trading day [1] - The opening price on the same day was 48.10 yuan, with a high of 48.50 yuan and a low of 46.39 yuan, and the trading volume reached 92,278 hands with a transaction amount of 436 million yuan [1] - Tibet Pharmaceutical operates in the biopharmaceutical industry, with its registered location in Lhasa, Tibet, and its product range includes traditional Chinese medicine, Tibetan medicine, and biological products [1] Group 2 - On August 21, during the morning trading session, the stock price of Tibet Pharmaceutical experienced a rapid decline, dropping over 2% within five minutes [1] - At 9:35 AM, the stock price was reported at 47.40 yuan, with a transaction amount of approximately 96 million yuan [1] - Data on capital flow indicates a net outflow of 1.05 million yuan from main funds on that day, accounting for 0.01% of the circulating market value, while the cumulative net inflow over the past five trading days was 7.99 million yuan, representing 0.05% of the circulating market value [1]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company has maintained stable sales of its core product, Xinhuasu, and is continuously developing a "second growth curve" through the introduction of new products and expansion into new markets [5][7] - The company reported a revenue of 1.651 billion yuan in the first half of 2025, an increase of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [7] - The company expects Xinhuasu sales to stabilize in 2025, with new production capacity set to be released, which will help alleviate production bottlenecks [7] - The company is also focusing on expanding its product range, with other products generating a revenue of 192 million yuan in the first half of 2025, an increase of 18.83% [7] - The company has invested in Chen Tai Pharmaceutical, acquiring a 13.04% stake, and has signed an exclusive distribution agreement for Zolotinin, which is expected to enhance its product portfolio [7] Financial Summary - Revenue projections for the company are as follows: 2.929 billion yuan in 2025, 3.168 billion yuan in 2026, and 3.513 billion yuan in 2027, with growth rates of 4.4%, 8.2%, and 10.9% respectively [6][7] - The net profit attributable to shareholders is projected to be 983 million yuan in 2025, 1.045 billion yuan in 2026, and 1.152 billion yuan in 2027, with growth rates of -6.5%, 6.3%, and 10.2% respectively [6][7] - The company's current price-to-earnings (PE) ratios are projected to be 15.6, 14.6, and 13.3 for the years 2025, 2026, and 2027 respectively [6][7]

金融界8月18日消息，上证指数高开高走，中证价值回报量化策略指数 (价值回报，930949)报13040.41 点。 数据统计显示，中证价值回报量化策略指数近一个月上涨4.88%，近三个月上涨6.40%，年至今上涨 3.53%。 从中证价值回报量化策略指数持仓样本的行业来看，工业占比40.89%、可选消费占比19.63%、通信服 务占比11.10%、医药卫生占比9.18%、能源占比6.57%、主要消费占比6.31%、原材料占比3.88%、房地 产占比2.43%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年5月和11月的第六个交易日。权重 因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期调整日前，权 重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样 本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 从指数持仓来看，中证价值回报量化策略指数十大权重分别为：匠心家居（2.32%）、达仁堂 （1.9%）、吉比特（1.88%）、博隆技术（1.78%）、阳光电源（1.74%）、方大特钢（1.59%）、江河 集团（1. ...